Five Prime Therapeutics, Inc.
(NASDAQ : FPRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.08%109.411.1%$637.77m
GILDGilead Sciences, Inc.
1.66%75.570.9%$577.68m
AMGNAmgen Inc.
1.13%176.901.1%$506.89m
REGNRegeneron Pharmaceuticals, Inc.
1.52%388.952.7%$352.74m
BIIBBiogen Inc.
1.36%327.941.2%$335.33m
ALXNAlexion Pharmaceuticals, Inc.
2.36%115.761.9%$262.11m
VRTXVertex Pharmaceuticals Incorporated
2.34%145.861.9%$218.93m
BLUEBluebird Bio, Inc.
-0.76%182.9516.1%$207.25m
ILMNIllumina, Inc.
2.70%216.553.5%$180.07m
ALNYAlnylam Pharmaceuticals, Inc
1.56%125.5910.0%$167.77m
AAgilent Technologies, Inc.
1.64%67.601.5%$158.47m
NKTRNektar Therapeutics
3.36%56.906.1%$157.89m
INCYIncyte Corporation
0.46%96.412.5%$142.11m
BMRNBioMarin Pharmaceutical Inc.
5.07%93.024.4%$114.48m
JUNOJuno Therapeutics, Inc.
1.16%44.6813.5%$102.38m

Company Profile

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.